Skip to main content
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. - Investor Relations & Filings

Listed
Ticker · INM ISIN · CA4576375022 LEI · 549300VA5DNHEJGHG397 US Manufacturing
Open in API
Filings indexed 472 across all filing types
Latest filing 2026-07-22 M&A Activity
Country CA Canada
Listing US INM

Key figures FY2024

Period ended 2024-06-30 · USD
Headline annual figures for InMed Pharmaceuticals Inc., fiscal year 2024, reported in USD, with the source filing for each figure.
Total Revenues USD 4.60M per the Annual Report filed 2024-09-28
Net Income USD -7.68M per the Annual Report filed 2024-09-28
Total Assets USD 11.82M per the Annual Report filed 2024-09-28
Total Equity USD 9.21M per the Annual Report filed 2024-09-28
Cash from Ops USD -6.99M per the Annual Report filed 2024-09-28

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About InMed Pharmaceuticals Inc.

https://www.inmedpharma.com/

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that target the CB1 and CB2 cannabinoid receptors. The company's therapeutic pipeline includes preclinical programs for Alzheimer's disease (INM-901) and dry age-related macular degeneration (INM-089). In dermatology, InMed has completed a Phase 2 clinical trial for the treatment of epidermolysis bullosa. Additionally, its subsidiary, BayMedica, manufactures and supplies high-purity, rare cannabinoids such as cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), and cannabidivarin (CBDV) as raw ingredients for the business-to-business health and wellness market.

Recent filings

Filing Released Lang Actions
FORM 425
M&A Activity
2026-07-22 English
CURRENT REPORT
M&A Activity
2026-07-22 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a US SEC Form 8-K Current Report filed by InMed Pharmaceuticals Inc., detailing recent corporate events, M&A amendments, and financing activities (such as an amendment to a securities purchase agreement for a merger). According to the filing categories, general regulatory announcements, compliance documents, and US SEC Form 8-K filings that serve as miscellaneous general regulatory filings without a more specific financial report match fall under Regulatory Filings (RNS).
2026-07-22 English
FORM 425
M&A Activity
2026-07-20 English
CURRENT REPORT
M&A Activity
2026-07-10 English
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC by InMed Pharmaceuticals Inc. It details an amendment to a merger agreement (Item 1.01) and provides a Regulation FD disclosure (Item 7.01). Since Form 8-K filings are general regulatory announcements used for material events that do not fit into specific financial report categories like 10-K or IR, and the document is a standard regulatory filing, it is classified as RNS.
2026-07-10 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.